

## Highlights of This Issue 915

### THERAPEUTIC DISCOVERY

- 917 **Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance**  
Milos Dokmanovic, Yi Shen, Tabettha M. Bonacci, Dianne S. Hirsch, and Wen Jin Wu
- 929 **Overexpression of Mitotic Centromere-Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel**  
Anutosh Ganguly, Hailing Yang, and Fernando Cabral
- 938 **Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype**  
Kaijie He, Tong Xu, and Amir Goldkorn
- 949 **The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3 $\beta$ -Dependent Pathway**  
Jenny E. Hernandez-Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser, and Kathleen M. Sakamoto
- 960 **B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation**  
Hao Liu, Christina Tekle, Yih-Wen Chen, Alexandr Kristian, Yuhua Zhao, Ming Zhou, Zixing Liu, Yan Ding, Bin Wang, Gunhild Mari Mælandsmo, Jahn Marthin Nesland, Oystein Fodstad, and Ming Tan
- 972 **Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors**  
Eric A. Murphy, Bharat K. Majeti, Rajesh Mukthavaram, Lisette M. Acevedo, Leo A. Barnes, and David A. Cheresh

- 983 **Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3**  
Tom Van Maerken, Ali Rihani, Daniel Dreidax, Sarah De Clercq, Nurten Yigit, Jean-Christophe Marine, Frank Westermann, Anne De Paepe, Jo Vandesompele, and Frank Speleman
- 994 **A Simplified Synthesis of Novel Dictyostatin Analogues with *In Vitro* Activity against Etoposide B-Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos**  
Laura L. Vollmer, Maria Jiménez, Daniel P. Camarco, Wei Zhu, Hikmat N. Daghestani, Raghavan Balachandran, Celeste E. Reese, John S. Lazo, Neil A. Hukriede, Dennis P. Curran, Billy W. Day, and Andreas Vogt

### PRECLINICAL DEVELOPMENT

- 1007 **Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma**  
Anne-Christine Piguet, Bettina Saar, Ruslan Hlushchuk, Marie V. St-Pierre, Paul M.J. McSheehy, Vesna Radojevic, Maresa Afthinos, Luigi Terracciano, Valentin Djonov, and Jean-François Dufour
- 1018 **The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells**  
Wei Fu, Le Ma, Baoky Chu, Xue Wang, Marilyn M. Bui, Jennifer Gemmer, Soner Altioek, and W. Jackson Pledger
- 1028 **Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies**  
Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell, Jeffrey W. Tyner, Marc M. Loriaux, Qurish K. Moheemad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Brian J. Druker, Tim Clackson, and Victor M. Rivera

1036 **Induction of *In Vitro* and *In Vivo* NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma**

Ron D. Jachimowicz, Giulio Fracasso, Paul J. Yazaki, Barbara E. Power, Peter Borchmann, Andreas Engert, Hinrich P. Hansen, Katrin S. Reiners, Elke Pogge von Strandmann, and Achim Rothe

1046 **ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance**

Julie Millour, Natalia de Olano, Yoshiya Horimoto, Lara J. Monteiro, Julia K. Langer, Rosa Aligue, Nabil Hajji, and Eric W-F. Lam

1059 **Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens**

Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iulucci, Frank Wang, and Tim Clackson

1072 **Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models**

Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan, and David M. Goldenberg

1082 **Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle**

Hong Yao, Samuel S. Ng, Long-Fei Huo, Billy K. C. Chow, Zan Shen, Min Yang, Johnny Sze, Otis Ko, Ming Li, Alexander Yue, Li-Wei Lu, Xiu-Wu Bian, Hsiang-Fu Kung, and Marie C. Lin

## MOLECULAR MEDICINE IN PRACTICE

1093 **PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer**

Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A. Barrera, Octavio Burgues, Ana M. Lluch, Huiqin Chen, Gabriel N. Hortobagyi, Gordon B. Mills, and Funda Meric-Bernstam

1102 **Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial**

Monika E. Hegi, Annie-Claire Diserens, Pierre Bady, Yuta Kamoshima, Mathilde C. M. Kouwenhoven, Mauro Delorenzi, Wanyu L. Lambiv, Marie-France Hamou, Matthias S. Matter, Arend Koch, Frank L. Heppner, Yasuhiro Yonekawa, Adrian Merlo, Karl Frei, Luigi Mariani, and Silvia Hofer


1113 **Hypoxia Induces Genomic DNA Demethylation through the Activation of HIF-1 $\alpha$  and Transcriptional Upregulation of MAT2A in Hepatoma Cells**

Quanyan Liu, Li Liu, Yuhong Zhao, Jin Zhang, Dongfeng Wang, Jiwei Chen, Yueming He, Jianguo Wu, Zhonglin Zhang, and Zhisu Liu

---

## ABOUT THE COVER

MCAK is a kinesin-related motor protein that stimulates microtubule depolymerization. It localizes to centrosomes and nuclei during interphase, and to spindle poles and chromosome centromeres during mitosis. The cover figure shows a mixture of non-transfected and FLAG-MCAK expressing cells that were stained for DNA (blue), FLAG-MCAK (green), and tubulin (red). MCAK overexpression increased the frequency of microtubule detachment from centrosomes, reduced the amount of microtubule polymer, and caused cells to exit from mitosis without cytokinesis, thereby producing large multinucleated cells with few and fragmented microtubules. The microtubule stabilizing drug paclitaxel was able to counteract the effects of MCAK overproduction. For details, see the article by Ganguly and colleagues on page 929.



# Molecular Cancer Therapeutics

**10 (6)**

*Mol Cancer Ther* 2011;10:915-1123.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/10/6>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/10/6>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.